Geriatric AnesthesiaNCT07544719
Systemic Immun Inflamation Score Corelation in Postoperative Patients Prognosis
An observational study of Geriatric Anesthesia and Postop Adult ICU Patients, run by Malatya Egitim Ve Arastirma Hastanesi.
Trial summary
The Systemic Immuno-Inflammation Index (SII) is a ratio derived from complete blood count parameters (neutrophils, lymphocytes, platelets) and is a non-invasive and easily calculable biomarker. The SIPI effectively reflects both local and systemic inflammatory responses in the human body. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Geriatric Anesthesia, Postop Adult ICU Patients
- How many people
- 150 participants
- Where
- No sites listed yet
- Study dates
- 15 Jun 2026to 30 Jul 2026
- How long will I take part?
- 30 Days
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: 65 years of age or older postoperative patients
Who may be able to join
- The patient must be 65 years of age or older (in the geriatric age group),
- Admitted to the intensive care unit after elective or emergency surgery
- Have access to complete blood count (hemogram) data (neutrophils, lymphocytes, platelets) during their stay in the intensive care unit
- Be able to undergo 30-day mortality monitoring from the date of admission to the intensive care unit
- Have provided informed consent from the patient or their legal representative.
Who cannot join
- Patients under 65 years of age
- Patients admitted to the intensive care unit for non-surgical reasons (e.g., trauma, medical intensive care indications)
- Patients with deficient neutrophil, lymphocyte, or platelet counts upon admission to the intensive care unit
- Patients with a history of malignancy, hematological disease, or immunosuppressive therapy
- Terminally ill palliative patients
- Patients who refuse informed consent.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Prognostic Value of Systemic Immun Inflamation Index in Geriatrik Patient Admitted to the ICU After Surgery: A Prospective Observational Study
The Systemic Immuno-Inflammation Index (SII) is a ratio derived from complete blood count parameters (neutrophils, lymphocytes, platelets) and is a non-invasive and easily calculable biomarker. The SIPI effectively reflects both local and systemic inflammatory responses in the human body. It has been used to predict and evaluate the prognosis of various solid tumors such as gastric cancer, non-small cell lung cancer, and colorectal cancer. Furthermore, the SIPI has been shown to have significant prognostic value in cardiovascular and cerebrovascular diseases. In this study, the SIPI will be calculated using laboratory data at the time of admission to the intensive care unit, and the relationship between the obtained values and the 30-day mortality status of the patients will be analyzed.
- Conditions
- Geriatric Anesthesia, Postop Adult ICU Patients
What is being measured
The primary outcome is the main question the study is designed to answer.
Measuring the Systemic Immune-Inflammation Index (SII) in postoperative patients to see the parameter's predictibility of 30-day mortality
In geriatric patients admitted to the intensive care unit after surgery, the Systemic Immune-Inflammation Index (SII) is a significant biomarker for predicting 30-day mortality.
Measured: Postoperative day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2026
- Study start15 Jun 2026 (estimated)
- Primary completion15 Jul 2026 (estimated)
- Study completion30 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Geriatric AnesthesiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
- Target duration
- 30 Days
Sponsor and investigators
- Lead sponsor
- Malatya Egitim Ve Arastirma Hastanesi
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Leman Acun Delen, Malatya Egitim Ve Arastirma Hastanesi
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07544719
- Sponsor's protocol ID
- MEAH-SII-ICU-2026-01
- Status last verified
- Jan 2026
- First submitted
- 9 Apr 2026
- Last updated
- 22 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, Chen CQ, He YL, Cai SR. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017 Sep 14;23(34):6261-6272. doi: 10.3748/wjg.v23.i34.6261.
PubMed 28974892Zeng QY, Qin Y, Shi Y, Mu XY, Huang SJ, Yang YH, Liu SM, An ZM, Li SQ. Systemic immune-inflammation index and all-cause and cause-specific mortality in sarcopenia: a study from National Health and Nutrition Examination Survey 1999-2018. Front Immunol. 2024 Apr 4;15:1376544. doi: 10.3389/fimmu.2024.1376544. eCollection 2024.
PubMed 38638440
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Value of Systemic Immun Inflamation Index in Geriatrik Patient Admitted to the ICU After Surgery: A Prospective Observational Study
- ClinicalTrials.gov ID
- NCT07544719
- Acronym / sponsor ID
- MEAH-SII-ICU-2026-01
- Conditions
- Geriatric Anesthesia, Postop Adult ICU Patients
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Malatya Egitim Ve Arastirma HastanesiOther government
- Study start
- 15 Jun 2026 (estimated)
- Primary completion
- 15 Jul 2026 (estimated)
- Study completion
- 30 Jul 2026 (estimated)
- First posted
- 22 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Systemic Immuno-Inflammation Index (SII) is a ratio derived from complete blood count parameters (neutrophils, lymphocytes, platelets) and is a non-invasive and easily calculable biomarker. The SIPI effectively reflects both local and systemic inflammatory responses in the human body. It has been used to predict and evaluate the prognosis of various solid tumors such as gastric cancer, non-small cell lung cancer, and colorectal cancer. Furthermore, the SIPI has been shown to have significant prognostic value in cardiovascular and cerebrovascular diseases. In this study, the SIPI will be calculated using laboratory data at the time of admission to the intensive care unit, and the relationship between the obtained values and the 30-day mortality status of the patients will be analyzed.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 30 Days
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- 65 years of age or older postoperative patients
Key inclusion criteria (5 listed)
- The patient must be 65 years of age or older (in the geriatric age group),
- Admitted to the intensive care unit after elective or emergency surgery
- Have access to complete blood count (hemogram) data (neutrophils, lymphocytes, platelets) during their stay in the intensive care unit
- Be able to undergo 30-day mortality monitoring from the date of admission to the intensive care unit
- Have provided informed consent from the patient or their legal representative.
Key exclusion criteria (6 listed)
- Patients under 65 years of age
- Patients admitted to the intensive care unit for non-surgical reasons (e.g., trauma, medical intensive care indications)
- Patients with deficient neutrophil, lymphocyte, or platelet counts upon admission to the intensive care unit
- Patients with a history of malignancy, hematological disease, or immunosuppressive therapy
- Terminally ill palliative patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Measuring the Systemic Immune-Inflammation Index (SII) in postoperative patients to see the parameter's predictibility of 30-day mortality
Time frame: Postoperative day 1
In geriatric patients admitted to the intensive care unit after surgery, the Systemic Immune-Inflammation Index (SII) is a significant biomarker for predicting 30-day mortality.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2026.
- Results publication: PubMed 28974892Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, Chen CQ, He YL, Cai SR. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017 Sep 14;23(34):6261-6272. doi: 10.3748/wjg.v23.i34.6261.
- Results publication: PubMed 38638440Zeng QY, Qin Y, Shi Y, Mu XY, Huang SJ, Yang YH, Liu SM, An ZM, Li SQ. Systemic immune-inflammation index and all-cause and cause-specific mortality in sarcopenia: a study from National Health and Nutrition Examination Survey 1999-2018. Front Immunol. 2024 Apr 4;15:1376544. doi: 10.3389/fimmu.2024.1376544. eCollection 2024.
Related trials for Geriatric Anesthesia
Not yet recruiting
Bispectral Index-Guided Propofol Sedation During Endoscopic Retrograde Cholangiopancreatography
Deep Sedation, Endoscopic Retrograde Cholangiopancreatography
RecruitingPhase 4
Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia
Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia
Not yet recruitingPhase 4
Effect of Ondansetron on the Incidence of Spinal Anaesthesia-Induced Hypotension in Elderly Patients Undergoing Fracture Hip Surgery
Spinal Anaesthesia Induced Hypotension
Not yet recruitingObservational study
Postprandial Hypotension, Frailty and Post-Induction Hypotension in Older Patients Undergoing Noncardiac Surgery
Post-induction Hypotension (PIH), Postprandial Hypotension
Not yet recruiting
Intracuff Dexmedetomidine Versus Alkalinized Lidocaine for Peri-Extubation Cough and Hemodynamic Responses in Elderly Patients
Airway Complication of Anesthesia, Hemodynamic Instability
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Geriatric Anesthesia and Postop Adult ICU Patients, run by Malatya Egitim Ve Arastirma Hastanesi.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ayşe Yılkınç Tekirdaş (+905395721741, ylknc.ys.44@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measuring the Systemic Immune-Inflammation Index (SII) in postoperative patients to see the parameter's predictibility of 30-day mortality (time frame: Postoperative day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07544719, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2026.